Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis

Koichi Suda, Hiroya Takeuchi, Tomoko Hagiwara, Taku Miyasho, Minoru Okamoto, Kazufumi Kawasako, Shingo Yamada, Kazuhiro Suganuma, Norihito Wada, Yoshiro Saikawa, Koichi Fukunaga, Yosuke Funakoshi, Satoru Hashimoto, Hiroshi Yokota, Ikuro Maruyama, Akitoshi Ishizaka, Yuukou Kitagawa

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Sivelestat sodium hydrate is a selective inhibitor of neutrophil elastase, which is effective in acute lung injury associated with systemic inflammatory response syndrome. However, the effectiveness of sivelestat in sepsis has not been fully examined. In the present study, the effect of sivelestat on severe sepsis in a rat cecal ligation and puncture (CLP) model was investigated. Adult male Sprague-Dawley rats underwent CLP and were randomly divided into two groups: sivelestat-treated group and saline-treated controls. The serum concentrations of several inflammatory mediators were measured. Hematoxylin-eosin staining, and immunohistochemical staining for high-mobility group box chromosomal protein 1 (HMGB1), IL-8, and CD68 were performed on the lungs to assess pathological changes found 12 h after the CLP procedure. Treatment with sivelestat significantly improved the survival rate of the post-CLP septic animals (P = 0.030). Sivelestat also induced a significant reduction in serum IL-1β (P = 0.038) and IL-10 (P = 0.008) levels in these CLP rats. Serum HMGB1 levels had no significant difference between the sivelestat-treated and the control group. The lungs from sivelestat-treated rats exhibited less severe pathological changes and decreased the numbers of HMGB1, IL-8, and CD68-positive cells (P < 0.001). Sivelestat significantly improved survival rate of rats with clinically relevant sepsis, possibly by attenuating sepsis-induced systemic inflammatory response and lung injury. This may explain the implicated health benefits of sivelestat in reducing morbidity and mortality from sepsis.

Original languageEnglish
Pages (from-to)526-531
Number of pages6
JournalShock
Volume33
Issue number5
DOIs
Publication statusPublished - 2010

Fingerprint

Secretory Proteinase Inhibitory Proteins
Sepsis
Punctures
Ligation
High Mobility Group Proteins
HMGB1 Protein
Interleukin-8
Survival Rate
Serum
sivelestat
Staining and Labeling
Systemic Inflammatory Response Syndrome
Lung
Acute Lung Injury
Lung Injury
Insurance Benefits
Hematoxylin
Eosine Yellowish-(YS)
Interleukin-1
Interleukin-10

Keywords

  • Cecal ligation and puncture
  • Cytokine
  • High-mobility group box chromosomal protein 1
  • Sivelestat
  • Systemic inflammatory response syndrome

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine
  • Medicine(all)

Cite this

Suda, K., Takeuchi, H., Hagiwara, T., Miyasho, T., Okamoto, M., Kawasako, K., ... Kitagawa, Y. (2010). Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. Shock, 33(5), 526-531. https://doi.org/10.1097/SHK.0b013e3181cc064b

Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. / Suda, Koichi; Takeuchi, Hiroya; Hagiwara, Tomoko; Miyasho, Taku; Okamoto, Minoru; Kawasako, Kazufumi; Yamada, Shingo; Suganuma, Kazuhiro; Wada, Norihito; Saikawa, Yoshiro; Fukunaga, Koichi; Funakoshi, Yosuke; Hashimoto, Satoru; Yokota, Hiroshi; Maruyama, Ikuro; Ishizaka, Akitoshi; Kitagawa, Yuukou.

In: Shock, Vol. 33, No. 5, 2010, p. 526-531.

Research output: Contribution to journalArticle

Suda, K, Takeuchi, H, Hagiwara, T, Miyasho, T, Okamoto, M, Kawasako, K, Yamada, S, Suganuma, K, Wada, N, Saikawa, Y, Fukunaga, K, Funakoshi, Y, Hashimoto, S, Yokota, H, Maruyama, I, Ishizaka, A & Kitagawa, Y 2010, 'Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis', Shock, vol. 33, no. 5, pp. 526-531. https://doi.org/10.1097/SHK.0b013e3181cc064b
Suda K, Takeuchi H, Hagiwara T, Miyasho T, Okamoto M, Kawasako K et al. Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. Shock. 2010;33(5):526-531. https://doi.org/10.1097/SHK.0b013e3181cc064b
Suda, Koichi ; Takeuchi, Hiroya ; Hagiwara, Tomoko ; Miyasho, Taku ; Okamoto, Minoru ; Kawasako, Kazufumi ; Yamada, Shingo ; Suganuma, Kazuhiro ; Wada, Norihito ; Saikawa, Yoshiro ; Fukunaga, Koichi ; Funakoshi, Yosuke ; Hashimoto, Satoru ; Yokota, Hiroshi ; Maruyama, Ikuro ; Ishizaka, Akitoshi ; Kitagawa, Yuukou. / Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis. In: Shock. 2010 ; Vol. 33, No. 5. pp. 526-531.
@article{044cad1eda5444619ad34db18b79682e,
title = "Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis",
abstract = "Sivelestat sodium hydrate is a selective inhibitor of neutrophil elastase, which is effective in acute lung injury associated with systemic inflammatory response syndrome. However, the effectiveness of sivelestat in sepsis has not been fully examined. In the present study, the effect of sivelestat on severe sepsis in a rat cecal ligation and puncture (CLP) model was investigated. Adult male Sprague-Dawley rats underwent CLP and were randomly divided into two groups: sivelestat-treated group and saline-treated controls. The serum concentrations of several inflammatory mediators were measured. Hematoxylin-eosin staining, and immunohistochemical staining for high-mobility group box chromosomal protein 1 (HMGB1), IL-8, and CD68 were performed on the lungs to assess pathological changes found 12 h after the CLP procedure. Treatment with sivelestat significantly improved the survival rate of the post-CLP septic animals (P = 0.030). Sivelestat also induced a significant reduction in serum IL-1β (P = 0.038) and IL-10 (P = 0.008) levels in these CLP rats. Serum HMGB1 levels had no significant difference between the sivelestat-treated and the control group. The lungs from sivelestat-treated rats exhibited less severe pathological changes and decreased the numbers of HMGB1, IL-8, and CD68-positive cells (P < 0.001). Sivelestat significantly improved survival rate of rats with clinically relevant sepsis, possibly by attenuating sepsis-induced systemic inflammatory response and lung injury. This may explain the implicated health benefits of sivelestat in reducing morbidity and mortality from sepsis.",
keywords = "Cecal ligation and puncture, Cytokine, High-mobility group box chromosomal protein 1, Sivelestat, Systemic inflammatory response syndrome",
author = "Koichi Suda and Hiroya Takeuchi and Tomoko Hagiwara and Taku Miyasho and Minoru Okamoto and Kazufumi Kawasako and Shingo Yamada and Kazuhiro Suganuma and Norihito Wada and Yoshiro Saikawa and Koichi Fukunaga and Yosuke Funakoshi and Satoru Hashimoto and Hiroshi Yokota and Ikuro Maruyama and Akitoshi Ishizaka and Yuukou Kitagawa",
year = "2010",
doi = "10.1097/SHK.0b013e3181cc064b",
language = "English",
volume = "33",
pages = "526--531",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis

AU - Suda, Koichi

AU - Takeuchi, Hiroya

AU - Hagiwara, Tomoko

AU - Miyasho, Taku

AU - Okamoto, Minoru

AU - Kawasako, Kazufumi

AU - Yamada, Shingo

AU - Suganuma, Kazuhiro

AU - Wada, Norihito

AU - Saikawa, Yoshiro

AU - Fukunaga, Koichi

AU - Funakoshi, Yosuke

AU - Hashimoto, Satoru

AU - Yokota, Hiroshi

AU - Maruyama, Ikuro

AU - Ishizaka, Akitoshi

AU - Kitagawa, Yuukou

PY - 2010

Y1 - 2010

N2 - Sivelestat sodium hydrate is a selective inhibitor of neutrophil elastase, which is effective in acute lung injury associated with systemic inflammatory response syndrome. However, the effectiveness of sivelestat in sepsis has not been fully examined. In the present study, the effect of sivelestat on severe sepsis in a rat cecal ligation and puncture (CLP) model was investigated. Adult male Sprague-Dawley rats underwent CLP and were randomly divided into two groups: sivelestat-treated group and saline-treated controls. The serum concentrations of several inflammatory mediators were measured. Hematoxylin-eosin staining, and immunohistochemical staining for high-mobility group box chromosomal protein 1 (HMGB1), IL-8, and CD68 were performed on the lungs to assess pathological changes found 12 h after the CLP procedure. Treatment with sivelestat significantly improved the survival rate of the post-CLP septic animals (P = 0.030). Sivelestat also induced a significant reduction in serum IL-1β (P = 0.038) and IL-10 (P = 0.008) levels in these CLP rats. Serum HMGB1 levels had no significant difference between the sivelestat-treated and the control group. The lungs from sivelestat-treated rats exhibited less severe pathological changes and decreased the numbers of HMGB1, IL-8, and CD68-positive cells (P < 0.001). Sivelestat significantly improved survival rate of rats with clinically relevant sepsis, possibly by attenuating sepsis-induced systemic inflammatory response and lung injury. This may explain the implicated health benefits of sivelestat in reducing morbidity and mortality from sepsis.

AB - Sivelestat sodium hydrate is a selective inhibitor of neutrophil elastase, which is effective in acute lung injury associated with systemic inflammatory response syndrome. However, the effectiveness of sivelestat in sepsis has not been fully examined. In the present study, the effect of sivelestat on severe sepsis in a rat cecal ligation and puncture (CLP) model was investigated. Adult male Sprague-Dawley rats underwent CLP and were randomly divided into two groups: sivelestat-treated group and saline-treated controls. The serum concentrations of several inflammatory mediators were measured. Hematoxylin-eosin staining, and immunohistochemical staining for high-mobility group box chromosomal protein 1 (HMGB1), IL-8, and CD68 were performed on the lungs to assess pathological changes found 12 h after the CLP procedure. Treatment with sivelestat significantly improved the survival rate of the post-CLP septic animals (P = 0.030). Sivelestat also induced a significant reduction in serum IL-1β (P = 0.038) and IL-10 (P = 0.008) levels in these CLP rats. Serum HMGB1 levels had no significant difference between the sivelestat-treated and the control group. The lungs from sivelestat-treated rats exhibited less severe pathological changes and decreased the numbers of HMGB1, IL-8, and CD68-positive cells (P < 0.001). Sivelestat significantly improved survival rate of rats with clinically relevant sepsis, possibly by attenuating sepsis-induced systemic inflammatory response and lung injury. This may explain the implicated health benefits of sivelestat in reducing morbidity and mortality from sepsis.

KW - Cecal ligation and puncture

KW - Cytokine

KW - High-mobility group box chromosomal protein 1

KW - Sivelestat

KW - Systemic inflammatory response syndrome

UR - http://www.scopus.com/inward/record.url?scp=77951476335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951476335&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e3181cc064b

DO - 10.1097/SHK.0b013e3181cc064b

M3 - Article

C2 - 19953005

AN - SCOPUS:77951476335

VL - 33

SP - 526

EP - 531

JO - Shock

JF - Shock

SN - 1073-2322

IS - 5

ER -